Imkeldi — CareFirst (Caremark)
Chronic Graft-Versus-Host Disease (cGVHD)
Preferred products
- Gleevec
- imatinib mesylate
Initial criteria
- Used as subsequent therapy in combination with systemic corticosteroids
Reauthorization criteria
- No evidence of unacceptable toxicity or disease progression while on current regimen
Approval duration
12 months